摘要特应性皮炎是一种常见的慢性炎症性皮肤病，以湿疹样皮疹和剧烈瘙痒为主要表现，可严重影响患者生活质量。中重度特应性皮炎往往需要系统治疗，传统的系统治疗对部分患者效果不佳或不能耐受。近年来，生物制剂开始用于临床治疗特应性皮炎，其中白细胞介素4受体拮抗剂度普利尤单抗已经在我国上市。中华医学会皮肤性病学分会特应性皮炎研究中心、中华医学会皮肤性病学分会儿童学组组织本领域部分专家讨论度普利尤单抗在中重度特应性皮炎治疗中的应用，并形成共识，希望本共识能为我国皮肤科医生临床应用度普利尤单抗治疗特应性皮炎提供参考。

abstractsAtopic dermatitis is a chronic inflammatory skin disease, characterized by eczematous dermatitis and severe pruritus, and has severe impact on patients′ quality of life. Patients with moderate to severe atopic dermatitis often require systemic treatments, but traditional systemic treatments are ineffective or intolerable in some patients. In recent years, several biological agents have been applied to the treatment of atopic dermatitis in clinical practice, among which the interleukin-4 receptor antagonist dupilumab has been marketed in China. Some experts in related fields from Working Group for Atopic Dermatitis, Chinese Society of Dermatology and Working Group for Children′s Diseases, Chinese Society of Dermatology discussed the application of dupilumab in the treatment of moderate to severe atopic dermatitis, and developed a consensus, in the hope of providing a reference for the clinical application of dupilumab in the treatment of atopic dermatitis.